While ATRA induced differentiation of MDSC into myeloid dendritic cells in vitro (Gabrilovich et al., 2001), administration in vivo increased MDSC differentiation and enhanced CD4+ and CD8+ T cell antigen specific immune responses, but did not decrease tumor burden (Gabrilovich and Nagaraj, 2009). The gene discussed is CD8A; the disease is neoplasm.